EpiCast Report on Meningococcal Disease Market Epidemiology Forecast to 2025 | Researchmoz

Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis), an encapsulated gram-negative diplococcus that is a pathogen exclusive to humans. N. meningitidis is carried harmlessly in the nasopharynx of approximately 5?11% of adults and up to 25% of adolescents. Life-threatening disease occurs when the bacterium invades body tissue, which most commonly manifests as meningitis or septicemia. The disease is transmitted via respiratory droplets, through close or prolonged contact with an infected individual. N. meningitidis is classified into 13 distinct serogroups; however, almost all invasive disease in humans is a result of infection with one of 6 serogroups.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=741525

In the 8MM, GlobalData epidemiologists forecast that the laboratory-confirmed incident cases of IMD will decrease from 4,153 cases in 2015 to 3,169 cases in 2025 at an Annual Growth Rate (AGR) of negative 2.37%. Brazil had the highest number of laboratory-confirmed incident cases of IMD among the individual markets of the 8MM throughout the forecast period. The 5EU combined will account for 45.32% of laboratory-confirmed incident cases in 2015, and by 2025 this is forecast to increase to 59.58%. In the 8MM in 2015, 43.37% of the laboratory-confirmed incident cases of IMD are serogroup C disease, 36.46% are serogroup B disease, 5.25% are serogroup Y disease, and 14.98% are disease caused by other serogroups combined. GlobalData epidemiologists estimated that in the 8MM in 2015, 10.86% of laboratory-confirmed incident cases of IMD would occur in the population less than 1 year of age.

Scope

- The Meningococcal disease (IMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IMD in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). For the US, 5EU (France, Germany, Italy, Spain, and UK), and Brazil, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of all IMD (all serogroups combined), segmented by sex and age (in age groups of